Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants
NCT05324982Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabigerol (5 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Drug Effect Questionnaire at 8 hours, Heart rate at 8 hours and 11 more. Started Aug 2022; status: completed.
02
Drugs
cannabigerol
Beyond the preview
Go deeper on NCT05324982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324982.